Dougall W - Search Results

1

RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model.

Ignatoski KM, Escara-Wilke JF, Dai JL, Lui A, Dougall W, Daignault S, Yao Z, Zhang J, Day ML, Sargent EE, Keller ET. Ignatoski KM, et al. Among authors: dougall w. Prostate. 2008 Jun 1;68(8):820-9. doi: 10.1002/pros.20744. Prostate. 2008. PMID: 18324676 Free PMC article.

2

Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.

Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET. Zhang J, et al. Among authors: dougall w. Cancer Res. 2003 Nov 15;63(22):7883-90. Cancer Res. 2003. PMID: 14633717

3

RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.

Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC. Armstrong AP, et al. Prostate. 2008 Jan 1;68(1):92-104. doi: 10.1002/pros.20678. Prostate. 2008. PMID: 18008334 Free article.

4

Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.

Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC. Canon JR, et al. Clin Exp Metastasis. 2008;25(2):119-29. doi: 10.1007/s10585-007-9127-1. Epub 2007 Dec 5. Clin Exp Metastasis. 2008. PMID: 18064531

5

RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis.

Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC. Miller RE, et al. Mol Cancer Ther. 2008 Jul;7(7):2160-9. doi: 10.1158/1535-7163.MCT-08-0046. Epub 2008 Jul 7. Mol Cancer Ther. 2008. PMID: 18606716

6

RANKL signaling in bone physiology and cancer.

Dougall WC. Dougall WC. Curr Opin Support Palliat Care. 2007 Dec;1(4):317-22. doi: 10.1097/SPC.0b013e3282f335be. Curr Opin Support Palliat Care. 2007. PMID: 18685382 Review.

7

Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.

Holland PM, Miller R, Jones J, Douangpanya H, Piasecki J, Roudier M, Dougall WC. Holland PM, et al. Cancer Biol Ther. 2010 Apr 1;9(7):539-50. doi: 10.4161/cbt.9.7.11266. Epub 2010 Apr 1. Cancer Biol Ther. 2010. PMID: 20150760 Free article.

8

Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis.

Canon J, Bryant R, Roudier M, Osgood T, Jones J, Miller R, Coxon A, Radinsky R, Dougall WC. Canon J, et al. Bone. 2010 Jun;46(6):1613-9. doi: 10.1016/j.bone.2010.03.001. Epub 2010 Mar 6. Bone. 2010. PMID: 20215062

9

Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion.

Virk MS, Alaee F, Petrigliano FA, Sugiyama O, Chatziioannou AF, Stout D, Dougall WC, Lieberman JR. Virk MS, et al. Bone. 2011 Mar 1;48(3):578-87. doi: 10.1016/j.bone.2010.11.003. Epub 2010 Nov 10. Bone. 2011. PMID: 21073986 Free PMC article.

10

RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.

Canon J, Bryant R, Roudier M, Branstetter DG, Dougall WC. Canon J, et al. Breast Cancer Res Treat. 2012 Oct;135(3):771-80. doi: 10.1007/s10549-012-2222-2. Epub 2012 Aug 29. Breast Cancer Res Treat. 2012. PMID: 22926264

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

95 results

Search Page

Filters